Engitix has inked an R&D deal focused on fibrosis and liver tumors with new investor Dompé Farmaceutici S.p.A. that it hopes will facilitate the UK biotech’s transition from a technology platform to a clinical product company, as it raised $54m in a series A financing.
Under the collaboration, Engitix will retain full control over its assets and programs while Dompé could receive clinical and commercial...






